Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Tranexamic Acid

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00684879Completed

Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia

NCT00355108Phase 3Completed

ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome

Showing all 2 trials

Research Network

Common Treatments

  • Tranexamic Acid1

Active Sponsors

  • Hospices Civils de Lyon1
  • National Human Genome Research Institute (NHGRI)1

Top Investigators

Related Conditions

  • Telangiectasia Hereditary Hemorrhagic2
  • Oslerrenduweber Disease1

Activity Timeline